The benefit assessment by Germany's Federal Joint Committee (G-BA) indicated that US biotech firm PTC Therapeutics’ (Nasdaq: PTCT) Translarna (ataluren) provided a benefit for ambulatory patients aged five years and older with nonsense mutation Duchenne muscular dystrophy (nmDMD).
Translarna received conditional marketing authorization from the European Commission last year and was launched in Germany at the end of 2014 (The Pharma Letter December 3, 2014). It is still an investigational drug in the USA.
The G-BA came to the decision that the existing clinical data package presented by PTC provided convincing evidence for the demonstration of a clinically meaningful added benefit. PTC received a 3 in the rating system established under the German pharmaceutical law, the company noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze